Search
New Hampshire Paid Clinical Trials
A listing of 350 clinical trials in New Hampshire actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
337 - 348 of 350
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Dementia
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Alzheimer's Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
The Redwood Study is currently enrolling adults 18 to 75 years of age with Alpha-1
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
International Weight Control Registry
Recruiting
The IWCR is a global scientific study aimed at better understanding the opportunities and barriers for reducing the prevalence of obesity by collecting information from people who have experience with weight management in their everyday lives. The investigators seek to gather information on a wide range of weight management experiences, ranging from weight loss and weight loss maintenance to weight gain and inability to lose weight.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2022
Locations: University of New Hampshire, Durham, New Hampshire
Characterizing In Vivo Oral Lesion Impedances
Recruiting
The primary objective of this study is to demonstrate a significant difference in electrical impedance between normal, benign, premalignant, and malignant oral lesions using a custom device. The secondary study objective is to create a database of in vivo electrical impedance spectra and images of oral lesions. This will be achieved by collecting Electrical Impedance sensing data and images from two cohorts of patients: Cohort I will consist of 200 patients undergoing oral lesion biopsies and Co... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2022
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Oral Lesion
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Recruiting
This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer (mCRPC or M0CRPC) treated with darolutamide or enzalutamide. Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive ass... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
11/28/2022
Locations: New Hampshire Oncology and Hematology, Hooksett, New Hampshire
Conditions: Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer
STAMP+CBT mHealth for Cancer Pain
Recruiting
The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2022
Locations: Dana-Farber at Londonderry, Londonderry, New Hampshire
Conditions: Active Cancer, Active Cancer Treatment, Advanced Cancer, Palliative Care, Chronic Pain Due to Cancer
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
How is Social Connection Represented in the Brain?
Recruiting
Nearly half of the U.S. population sometimes or always experiences loneliness, which is alarming given that loneliness confers risk for negative mental and physical health outcomes. Extensive research suggests loneliness is characterized by subjective isolation: many lonely individuals maintain a number of relationships but still report feeling lonely. The goal of this proposal is to use functional magnetic resonance imaging to reveal how the brain represents our subjective connection to and iso... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/04/2022
Locations: Dartmouth College, Hanover, New Hampshire
Conditions: Loneliness
Connect® Myeloid Disease Registry
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: VA Medical Center Manchester, Manchester, New Hampshire
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Mindful Moms in Recovery
Recruiting
The purpose of this study is to evaluate the initial efficacy of a yoga-mindfulness intervention to promote ongoing recovery for pregnant and parenting women with Opioid Use Disorder (OUD) receiving perinatal services and medication treatment for OUD from maternity care practices in New Hampshire.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/03/2022
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Opioid-use Disorder
Struvite Stones Antibiotic Study
Recruiting
The aim of this research is to determine an effective antibiotic regimen following definitive surgical therapy of kidney stones caused by bacterial infection (struvite stones).
Gender:
All
Ages:
19 years and above
Trial Updated:
05/16/2022
Locations: Dartmouth University, Lebanon, New Hampshire
Conditions: Kidney Stones
Vermont RETAIN Impact Evaluation
Recruiting
The Retaining Employment and Talent after Injury/Illness Network (RETAIN) demonstration is a collaborative effort between the U.S. Department of Labor (DOL) and the Social Security Administration (SSA) to improve employment outcomes for individuals who experience injuries or illnesses that put them at risk of exiting the labor force and relying on disability programs and other public supports in the long term. RETAIN projects include a combination of medical provider services, stay-at-work/retur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/20/2022
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Disability
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Locally Advanced Pancreatic Cancer
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
Recruiting
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
Gender:
All
Ages:
Between 26 weeks and 31 weeks
Trial Updated:
02/22/2022
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Respiratory Distress Syndrome in Premature Infant